Conference Coverage

ACIP approves flu vaccine recommendations for 2019-2020 season


 

REPORTING FROM AN ACIP MEETING

All individuals aged 6 months and older should receive the influenza vaccine by the end of October next season, according to the Centers for Disease Control and Prevention’s Committee on Immunization Practices. The committee voted unanimously to accept minor updates to the ACIP flu recommendations for the 2019-2020 season, but no major changes were made from recent years.

A close-up of medical syringe with a vaccine. MarianVejcik/Getty Images

The past flu season was moderate overall, but notable for two waves of viral infections of similar magnitude, one with H1N1 and another with H3N2, said Lynette Brewer of the CDC’s National Center for Immunization and Respiratory Diseases, who presented data on last year’s flu activity.

Last year’s vaccine likely prevented between 40,000 and 90,000 hospitalizations, but mostly reduced the burden of H1N1 disease and provided no real protection against H3N2, she said.

The recommended H3N2 component for next season is A/Kansas/14/2017–like virus, which is genetically similar to the H3N2 that circulated last year.

Lisa Grohskopf, MD, of the CDC’s influenza division, presented the minor adjustments that included the changes in vaccine composition for next year, some licensure changes, and a new table summarizing dose volumes. Also, language was changed to advise vaccination for all eligible individuals by the end of October, and individuals who need two doses should have the first one as soon as it becomes available, in July or August if possible. The updated language also clarified that 8 year olds who need two doses should receive the second dose, even if they turn 9 between the two doses.

Additional guidance updates approved by the committee included harmonizing language on groups that should be the focus of vaccination in the event of limited supply to be more consistent with the 2011 ACIP Recommendations for the Immunization of Health Care Personnel.

The committee also voted unanimously to accept the proposed influenza vaccine in the Vaccines for Children program; there were no changes in recommended dosing intervals, dosages, contraindications, or precautions, according to Frank Whitlach of the National Center for Immunization and Respiratory Diseases, who presented the Vaccines for Children information.

The ACIP members had no financial conflicts to disclose.

Recommended Reading

Gaps exist in rotavirus vaccination coverage in young U.S. children
Journal of Clinical Outcomes Management
Measles cases for 2019 now at postelimination high
Journal of Clinical Outcomes Management
FDA approves first vaccine for prevention of dengue disease
Journal of Clinical Outcomes Management
United States up to 764 measles cases for the year
Journal of Clinical Outcomes Management
U.S. measles cases climb to over 800 for the year
Journal of Clinical Outcomes Management
Measles cases now at highest level since 1992
Journal of Clinical Outcomes Management
How to have ‘the talk’ with vaccine skeptics
Journal of Clinical Outcomes Management
Booster vaccines found largely safe in children on immunosuppressive drugs
Journal of Clinical Outcomes Management
U.S. travelers to Europe need up to date measles immunization
Journal of Clinical Outcomes Management
ACIP extends HPV vaccine coverage
Journal of Clinical Outcomes Management